Senescence and the early ageing phenotype after chemotherapy for testicular cancer: the SEA-CAT study

Recruiting

Conditions: Testicular cancer
10038364

Registration Number: NL-OMON52734

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 192

Inclusion Criteria

Cross-sectional part of this study:
- Diagnosed with metastatic testicular cancer in 1999-2019 and participated in
the above mentioned longitudinal studies (stage II or higher)
- Received first-line cisplatin-based chemotherapy
- Was younger than 50 years of age at start of chemotherapy, Longitudinal part
of this study:
Chemotherapy-group:
- Diagnosis of metastatic testicular cancer (stage II or higher)
- Is about to start with first-line cisplatin-based chemotherapy
- Younger than 50 years of age at diagnosis of metastatic testicular cancer,
Stage I control-group:
- Diagnosis of testicular cancer stage I disease
- Younger than 50 years of age at diagnosis of testicular cancer

In order to be eligible to participate in the control group of this study, a
subject must meet all of the following criteria:
Healthy control-group:
- Male younger than 60 years of age

Exclusion Criteria

- Earlier diagnosis with another malignancy except from successfully treated
squamous cell carcinoma of the skin.
- Not able to provide informed consent (in example in case of mental or
psychiatric disability)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>In the cross-sectional part of this study the primary endpoint is correlation<br /><br>between senescence and the early ageing phenotype. The amount of senescent<br /><br>cells in skin and fat tissue will be correlated with the early ageing phenotype<br /><br>defined as<br /><br>a) vascular stiffness (pulse wave velocity, PWV), the gold standard measurement<br /><br>for vascular age and<br /><br>b) the metabolic syndrome.<br /><br><br /><br>In the longitudinal part of the study the primary endpoint will be to<br /><br>investigate the development of senescent burden during cisplatin-combination<br /><br>chemotherapy. The percentage, and -if any- upregulation of senescent cells in<br /><br>skin and fat tissue will be measured and compared between pre-chemotherapy<br /><br>measurements and the different time points afterwards and compared between the<br /><br>chemotherapy group, the stage I control group and the healthy control group.</p><br>

Secondary Outcome Measures